CN Stock MarketDetailed Quotes

002437 Harbin Gloria Pharmaceuticals

Watchlist
  • 1.93
  • +0.04+2.12%
Market Closed Jul 5 15:00 CST
4.38BMarket Cap28.81P/E (TTM)

About Harbin Gloria Pharmaceuticals Company

Since its launch in 2010, the company has been adhering to the “product leading” strategy, and has enriched the company's product line through various methods such as epitaxial mergers and acquisitions, cooperative agents, independent research and development, and overseas introduction, etc., and has expanded from the narrow and single orthopedic treatment field at the beginning of the listing to the existing major treatment fields such as cardiovascular and cerebrovascular fields, skeletal muscle fields, nutritional medicine, etc., and a new pattern of multi-product-driven performance growth has gradually emerged. The company is mainly engaged in R&D, production and sales of pharmaceuticals. The company's main products include amlodipine tablets, sodium creatine phosphate for injection, ginkgo damole injections, olmesartan amlodipine tablets, edoxaban tablets, pravastatin tablets, carvastatin sodium tablets, sodium hyaluronate injections, multivitamin (12) compound vitamin (3) injections, potassium chloride sustained-release tablets, injectable potassium magnesium aspartate, sodium deoxynucleotide sodium injection (DNA), levocarnitine injection, and compound glycyrrhizinate for injection Ammonium S, cefaclor for injection, compound cefaclor capsules, calcium levofolate for injection, fluorouracil for injection, Cyclophosphamide for injection, Pingyangmycin hydrochloride for injection, silodosin capsules, etc. Corporate honors: In October 2018, Yuheng Pharmaceutical won the title of 2018 Top 100 Comprehensive Strength Industrial Enterprises in China's Chemical and Pharmaceutical Industry. In July 2018, Yuheng Pharmaceutical was listed as one of the “Top 100 Pharmaceutical Industries in China”. In June 2018, Yuheng Pharmaceutical won two awards: “2017 China's Top 100 Pharmaceutical Industry” and “2017 China Pharmaceutical Law-abiding and Honest Enterprise”. In May 2018, Yuheng Pharmaceutical won the 2018 Brand Value Assessment Enterprise Brand List, “2022 Top 100 Chinese Chemical Companies”, “Specialized and New” SMEs, “2022 Outstanding Private Enterprises in Datong City”, “2022 Outstanding Tax Contribution Award”, “Outstanding Economic Contribution Enterprise Award”, and “Outstanding Tax Contribution Enterprise Award”.

Company Profile

Short Name-A誉衡药业
Symbol-A002437
Company NameHarbin Gloria Pharmaceuticals Co., Ltd.
Listing DateJun 23, 2010
Issue Price50.00
Shares Offered35.00M share(s)
FoundedMar 27, 2000
Listed ExchangeSZ Stock Exchange
Legal Representativejin hu
General Managerleifeng guo
Secretaryyueyin liu
Accounting FirmShanghui Accounting Firm (special general partnership)
Securities Representativexuelong bai
Legal CounselBeijing Jingxuan Law Firm
Employees59
Phone010-80479607
Office AddressBuilding 28, Ronghuiyuan, Yuhua Road, Area B, Airport Development Zone, Shunyi District, Beijing
Zip Code101318
Registered AddressNo. 29, Beijing Road, Limin Economic and Technological Development Zone, Hulan District, Harbin, Heilongjiang
Fax010-68002438-607
Emailirm@gloria.cc
Business License230000400002254
BusinessManufacture and sale of tablets, capsules, granules, acupuncture powders (all cephalosporins), powder (hormones), dry suspensions, small-volume injections (including antitumor drugs), freeze-dried powder injections (including antitumor drugs, cephalosporins), suppositories, APIs (qinlongbutin, yankuning, etomide, fluorbiprofen), imported drug packaging (injections (injections (injections) (sodium hyaluronate injections); technical consultation, process technology transfer, technology development.

Company Executives

  • Name
  • Position
  • Salary
  • jin hu
  • Chairman,directors,Strategy Committee Members,Audit Committee Member
  • 2.16M
  • kang zhou
  • directors,Deputy General Manager
  • 1.86M
  • leifeng guo
  • directors,general manager,Head of finance,Nomination Committee Members,Remuneration and Assessment Committee Members
  • 2.16M
  • dongxu wang
  • directors
  • 1.90M
  • xiaodan zhang
  • Independent directors,Remuneration and Assessment Committee Members,Strategy Committee Members,Nomination Committee Members,Audit Committee Members
  • 200.00K
  • min pan
  • Independent directors,Audit Committee Members,Remuneration and Assessment Committee Members
  • 200.00K
  • yueyin liu
  • Board Secretary,Deputy General Manager,Head of Risk Control Center
  • 1.15M
  • xuelong bai
  • Securities affairs representative
  • --
  • hongzhen ma
  • Chairman of the Supervisory Board,Shareholder Supervisors
  • --
  • ling yu
  • Shareholder Supervisors
  • --
  • runbao li
  • Deputy General Manager
  • 658.80K
  • xiaohang wang
  • Deputy General Manager
  • 650.00K
  • lina wang
  • Employee supervisors
  • 110.90K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
%Chg